Lisa Porter

Dr. Porter has over 20 years of experience in developing medicines for metabolic diseases with a focus on bringing innovative therapies to patients with high unmet needs. Before joining NPM she served as CMO, Metabolic Diseases for Eiger Biopharmaceuticals where she led clinical development for the orphan diseases postbariatric hypoglycemia and Hutchinson-Gilford Progeria Syndrome resulting in FDA breakthrough therapy designation for both programs. She has previously served as CMO for Dance BioPharma (now Aerami Therapeutics) and Vice President, Medical Development for Amylin Pharmaceuticals where she led the R&D efforts for the Amylin-Lilly Alliance culminating in the approval of the GLP-1 agonist Bydureon, the 1st once-weekly treatment for Type 2 diabetes. Prior to joining Amylin, Dr. Porter held progressively increasing leadership positions at GlaxoSmithKline Pharmaceuticals with responsibilities for the clinical strategy for Avandia and early obesity compounds and as Associate Medical Director for Zeneca Pharmaceuticals.

Dr. Porter earned a BS in Biology from the College of William & Mary, an MD from Duke University, and completed fellowship training in Endocrinology and Hypertension at Brigham and Women’s Hospital.